Ascendis Pharma A/S

From Verify.Wiki
Jump to: navigation, search
Ascendis Pharma A/S
Type Public
Industry BioTechnology
Founded 2007
Headquarters Capital Region of Denmark, Denmark
Key people 55 [1]
Investors Gilde Healthcare Partners, OrbiMed, RA Capital Management, Rock Springs Capital, Sofinnova Partners, Sofinnova Ventures, TechnoStart, Venrock, Vivo Capital [2]
Number of employees Jan Møller Mikkelsen (Co-Founder, President and CEO), Martin Auster (CBO), Michael Beckert (Chief Medical Officer (acting)), Thomas Soloway (CFO)

Ascendis Pharma A/S is an emerging pharmaceutical company which is creating improved, patentable versions of both currently marketed drugs and high-value development-stage opportunities. The company is built upon a novel transient linker technology, TransientLink, which conjugates peptides, proteins and small molecules to a carrier molecule in a reversible fashion. This unique reversibility allows an unmodified active drug to be released (unlinked) in the body in a precise, time-controlled fashion, creating a long-acting effect. Conventional conjugation technologies are unable to achieve this type of slow-release mechanism because the polymer cannot de-link from the drug. [3]


Ascendis Pharma A/S, a clinical stage biopharmaceutical company

  • It develops various prodrug therapies to treat unmet medical needs.
  • It is developing TransCon human growth hormone that has completed Phase II clinical trials in children and adults to treat growth hormone deficiency (GHD) and other indications
  • TransCon Treprostinil that has completed Phase I clinical trial for the treatment of pulmonary arterial hypertension, a life-threatening disease characterized by elevated blood pressure in the pulmonary arteries.
  • The company is also developing TransCon Peptides for the treatment of diabetes
  • TransCon Ranibizumab, a compound to support injection of ranibizumab.
  • It has strategic collaborations with Sanofi and Genentech



None Reported

Top 5 Recent Tweets

February 02, 2023quantisnow$ASND 📜 SEC Form SC 13G filed by Ascendis Pharma A/S

45 seconds delayed.
January 31, 2023HedgeFundRiskWhat Makes Ascendis Pharma A/S (ASND) an Attractive Investment Choice? - Yahoo Finance
January 29, 2023Tian_A1#Barclays PLC owns 12.89 million of Ascendis Pharma A/S #Stock [ ] Following the completion…

Top 5 Recent News Headlines

Top 5 Lifetime Tweets

Top 5 Lifetime News Headlines


Verification history